Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)

<p>Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 SAN DIEGO, Dec. 14, 2023 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the Company has opened enrollment in the HARMONY Study, a global, randomized pivotal Phase 3 clinical trial of pegtibatinase, a novel investigational enzyme replacement […]</p>
<p>The post <a href="https://forextv.com/top-news/travere-therapeutics-initiates-pivotal-phase-3-clinical-trial-of-pegtibatinase-for-the-treatment-of-classical-homocystinuria-hcu/">Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>